TAIZHOU, China, Oct. 18, 2021 /PRNewswire/ -- China SXT
Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the
"Company"), a specialty pharmaceutical company focusing on the
research, development, manufacturing, marketing, and sales of
Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced
TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs,
regular TCMPs, and TCM Homologous Supplements
("TCMHS") announced today that it recently received a new
Pharmaceutical Manufacturing Permit ("PMP") from Jiangsu Province
Medical Products Administration (JSMPA) with a new production scope
of lyophilization processing. The Company also passed its
pharmaceutical GMP compliance-inspection conducted by JSMPA for the
Company's new lyophilization production facility. The Company
believed that it will be the first Directly-Oral TCMP manufacturer
nationwide in China passing such a
GMP compliance-inspection for lyophilization processing.
Lyophilization processing, also known as freeze drying, is a
process of freezing raw materials or products and removing the
frozen water by sublimation (the ice turns directly into vapor
without the liquid phase in the vacuum). After the
lyophilization process, the raw materials or products become loose
and fragile, which remarkably improves their aqueous solubility.
Also, the dehydrated raw materials and products have extended shelf
life. More importantly, this process is helpful in the
manufacturing of products such as our Directly-Oral TCMPs and
After-Soaking-Oral TCMPs that contain temperature-sensitive
components as they are kept in a frozen and dry condition and
remain unchanged.
The manufacture of our Directly-Oral TCMP product, Luxuejing,
involves the lyophilization process, which helps us deliver much
better quality products. Luxuejing
is a precious Chinese medicine made from fresh bloods
of Cuerus Nippon, which is approved to be used for
approved indications including leukopenia, thrombocytopenia or
hypoimmunity, chronic anemia, aplastic anemia, erectile
dysfunction, and postoperative rehabilitation, "This permit for new
production scope of lyophilization processing will contribute
significantly to our continuous effort in leading research and
development of new advanced TCMPs and pursuit of higher quality of
the products. We believe it will further accelerate our R&D of
new Advanced TCMPs, which is expected to expand our market share
for the advanced Directly-Oral TCMP and After-Soaking-Oral TCMP
products," Mr. Feng Zhou, Chief Executive Officer of China SXT,
commented.
About China SXT Pharmaceuticals, Inc.
Founded in 2005 and headquartered in Taizhou City, Jiangsu
Province, China, China SXT Pharmaceuticals, Inc. is an
innovative pharmaceutical company focusing on the research,
development, manufacture, marketing and sales of traditional
Chinese medicine pieces, which is a type of Traditional Chinese
Medicine that has been processed to be ready for use. For more
information, please visit www.sxtchina.com
Safe Harbor Statement
This press release contains forward-looking statements as
defined by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events or performance, and
underlying assumptions and other statements that are other than
statements of historical facts. When the Company uses words such as
"may, "will, "intend," "should," "believe," "expect," "anticipate,"
"project," "estimate" or similar expressions that do not relate
solely to historical matters, it is making forward-looking
statements. Specifically, the Company's statements regarding the
closing of the proposed private placement are forward-looking
statements. Forward-looking statements are not guarantees of future
performance and involve risks and uncertainties that may cause the
actual results to differ materially from the Company's expectations
discussed in the forward-looking statements. These statements are
subject to uncertainties and risks including, but not limited to,
the following: the Company's goals and strategies; the Company's
future business development; product and service demand and
acceptance; changes in technology; the growth of the pharmaceutical
market, particularly the Traditional Chinese Medicine Pieces
("TCMPs") market, in China; reputation and brand; the impact
of competition and pricing; government regulations; fluctuations in
general economic and business conditions in China and the
international markets the Company serves and assumptions underlying
or related to any of the foregoing and other risks contained in
reports filed by the Company with the Securities and Exchange
Commission. For these reasons, among others, investors are
cautioned not to place undue reliance upon any forward-looking
statements in this press release. Additional factors are discussed
in the Company's filings with the U.S. Securities and Exchange
Commission, which are available for
review at www.sec.gov. The Company undertakes no
obligation to publicly revise these forward - looking
statements to reflect events or circumstances that arise after the
date hereof.
For more information, please contact:
At the Company:
Mr. Feng Zhou, CEO
Email: fzhou@sxtchina.com or ir@sxtchina.com
Phone: 86-523-8629-9087
View original
content:https://www.prnewswire.com/news-releases/china-sxt-pharmaceuticals-inc-obtained-a-new-pharmaceutical-manufacturing-permit-and-passed-its-gmp-compliance-inspection-301401774.html
SOURCE China SXT Pharmaceuticals, Inc.